扶正化瘀胶囊对抗病毒有效的乙型肝炎肝硬化患者外周血细胞因子的调节

摘要/Abstract

摘要： 目的观察扶正化瘀胶囊对抗病毒有效的乙型肝炎肝硬化患者外周血细胞因子的分泌、肝功能及肝硬化程度的影响。方法收集恩替卡韦抗病毒治疗有效的乙型肝炎肝硬化患者63例,将其分为扶正化瘀组(FZHY组)30例,均用恩替卡韦联合扶正化瘀胶囊治疗;对照组33例,均单用恩替卡韦治疗;另选20名健康体检者作为健康对照组。治疗1年后分别观察乙型肝炎肝硬化患者肝硬化程度(肝硬度扫描,FibroScan),肝功能(ALT、AST、Alb、TBil)。比较3组外周血细胞因子(IL-1α、IL-1β、IL-4、IL-6、IL-8、IL-10、IL-13、MCP-1、INF-γ、TNF-α、TGF-β1)表达。结果较治疗前FZHY组患者ALT(36.00±19.74 vs 22.82±9.32) IU/L、AST(48.08±26.38 vs 34.47±17.14) IU/L显著下降(P<0.05,P<0.01)。FZHY组肝硬度有所下降(22.53±20.80 vs 14.28±10.40) kPa(P<0.05)。治疗后,FZHY组患者TGF-β1(1107.12±414.36 vs 512.24±219.36) pg/mL,IL-13(33.23±17.95 vs 13.58±17.93) pg/mL显著下降(P<0.01)。结论扶正化瘀胶囊可以减少炎性因子的分泌,从而抑制抗病毒有效的乙型肝炎肝硬化患者的进展。

关键词: 扶正化瘀胶囊, 乙型肝炎肝硬化, 细胞因子, 肝硬度扫描

Abstract: Objective To investigate the effect of Fuzhenghuayu (FZHY) capsule on peripheral blood cytokines secretion, liver function and liver cirrhosis in hepatitis B-related cirrhosis patients with effectively antiviral therapy.Methods A total of 63 patients with hepatitis B-related cirrhosis treated with entecavir effectively were enrolled in this study, including 30 cases treated with entecavir combined with FZHY as FZHY group and 33 cases treated with entecavir only as control group. Twenty healthy cases were set as normal group. Liver cirrhosis, liver function [alanine aminotransferase (ALT), aspartate transaminase (AST), albumin (Alb), total bilirubin (TBiL)] and the secretion of peripheral blood cytokines interleukin (IL) -1α, IL-1β, IL-4, IL-6, IL-8, IL-10, IL-13, monocyte chemotactic protein (MCP)-1, interferon(IFN)-γ, tumor necrosis factor (TNF)-α, TGF-β1) were measured after one-year treatment, respectively.Results After treatment, the levels of ALT and AST decreased significantly in FZHY group (P<0.05, P<0.01). Liver stiffness in FZHY group (P<0.05) and control group were both decreased. Compared with that in control group, the levels of TGF-β1 and IL-13 declined significantly in FZHY group after treatment (P<0.01).Conclusion FZHY capsule could relieve the progress of liver cirrhosis in effectively antiviral patients through inhibiting the secretion of inflammatory cytokines.

Key words: Fuzhenghuayu capsule, Liver cirrhosis of hepatitis B, Cytokines, Liver stiffness scans

吴眉,徐列明. 扶正化瘀胶囊对抗病毒有效的乙型肝炎肝硬化患者外周血细胞因子的调节[J]. 肝脏, 2017, 22(12): 1094-1097.

WU Mei, XU Lieming.. The regulatory effect of Fuzhenghuayu capsule on peripheral blood cytokines in hepatitis B-related cirrhosis patients with effectively antiviral therapy[J]. Chinese Hepatolgy, 2017, 22(12): 1094-1097.

参考文献

[1] 聂红明,汪蓉,朱梅萍,等.不同临床状态的 HBV 感染相关肝病患者T淋巴细胞水平和主要细胞因子表达的比较.中西医结合肝病杂志,2015,25: 8-12.
[2] 段惠春,王学红,范仲麟,等.细胞因子失衡促进肝硬化形成的研究进展医学综述, 2010,16:1441-1444.
[3] Senties-Gomez MD, Galvez -Gastelum F J, Meza-Garcia E, et al. Hepatic fibrosis: role o f matrix metalloproteases and TGF beta .Gac MedMe x,2005,141: 315-322.
[4] 刘成,刘平,胡义扬,等.扶正祛瘀方治疗肝炎后肝硬化的临床观察.中西医结合肝病杂志,1993,3:1-4.
[5] 徐列明.中医药治疗肝纤维化和肝硬化的临床实践.中华肝脏病杂志, 2008,16:182-183.
[6] 谭春雨,谭善忠,蒋健,等.扶正化瘀方对肝纤维化大鼠肝脏明胶酶、TIMP-2和星状细胞凋亡的影响.上海中医药大学学报,2003,17:40-44.
[7] 姜春萌,刘成海,刘成.扶正化瘀胶囊对肝星状细胞激活的干预.中国中西医结合消化杂志,2003,11:280-283.
[8] 刘成海.基于肝组织微血管变化探讨补虚化瘀中药防治肝硬化的作用机制.中西医结合肝病杂志,2008,15:1-4.
[9] 中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指南(2010年版). 肝脏,2011, 16: 2-6.
[10] 中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年更新版). 肝脏,2015, 20: 915-932.
[11] 王吉耀.内科学.北京:人民卫生出版社,2005.
[12] 林利静,赵长青,陈高峰.FibroScan评判中医药抗肝纤维化疗效的价值.中华肝脏病杂志,2014,22:113-117.
[13] Liaw YF,Kao JII, Piratvisuth T, et al. Asain-pacific consensus statement on the management of chronic hepatitis B: a 2012 update.Hepatol Int,2012,6: 531-561.
[14] Yeo W, Chun SH.Hepatitis B viral load predicts survival of HCC patients undergoing sy stemic chemotherapy. Hepatology,2007, 45: 1382 -1389.
[15] 李莉,陈念,何柳,等.P53 和高迁移率族蛋白-1在不同程度慢性乙型肝炎后肝纤维化组织中的含量及其意义中南大学学报(医学版).2015,40:1217-1222.
[16] 金宇霆,李大伟,明雅南,等.对乙酰氨基酚肝损伤时炎性因子、趋化因子以及ToLL样受体表达的动态变化.肝脏,2016,21:24-38.
[17] Masubuchi Y, Bourdi M, Reilly TP, et al. Role of interleukin-6 in hepatic heat shovk protein expression and protection against acetaminophen-induced liver disease. Biochem Biophys Res Commun,2003,304:207-212.
[18] 岑瑜,郭晓云,姜海行.白介素-22在肝损伤中JAK-STAT3通路作用的研究进展.世界华人消化杂志,2015,23:2228-2233.
[19] Tiegs G. Cellular and cytokine-mediated mechanisms of inflammation and its modulation in immune-mediated liver injury. Z Gastroenterol,2007; 45: 63-70.
[20] 陈厚文,吴超,李香龙,等. IL-13促进肝形状细胞增殖和胶原蛋白表达.中国细胞生物学学报,2011, 33:873-879.
[21] 曹庆生,李志超,杨宝友,等.矮地茶黄酮对四氯化碳致小鼠急性肝损伤的保护作用.华西药学杂志,2016,31:43-45.
[22] Xu L, Gu J, Lu X, et al. Traditional Chinese Medicine Can Improve Liver Microcirculation and Reduce Portal Hypertension in Liver Cirrhosis. Intech, 2012:98-120.
[23] 顾杰,洪嘉禾,徐列明,等.扶正化瘀胶囊对肝硬化患者门脉血流动力学的影响.上海中医药杂志, 2005, 39: 31-32.
[24] 朱剑亮,黄耀羲,刘平,等. 319肝平胶囊对肝炎后肝硬化异常免疫功能的调整. 中国中医药科技,1994,1:23-25.